View in EDS HTML Full Text PDF Full Text

Characterization of the Open-Label Lead-In Period of Two Randomized Controlled Phase 3 Trials Evaluating Dapagliflozin, Saxagliptin, and Metformin in Type 2 Diabetes.

Saved in:
Bibliographic Details
Title: Characterization of the Open-Label Lead-In Period of Two Randomized Controlled Phase 3 Trials Evaluating Dapagliflozin, Saxagliptin, and Metformin in Type 2 Diabetes.
Authors: Mathieu C; Katholieke Universiteit Leuven, Leuven, Belgium. chantal.mathieu@uzleuven.be., Catrinoiu D; Spitalul Clinic Judetean de Urgenta Constanta, Constanţa, Romania., Ranetti AE; Carol Davila University of Medicine and Pharmacy, Bucharest, Romania., Johnsson E; AstraZeneca Gothenburg, Mölndal, Sweden., Hansen L; Bristol-Myers Squibb, Princeton, NJ, USA., Chen H; AstraZeneca, Gaithersburg, MD, USA., Garcia-Sanchez R; AstraZeneca, Gaithersburg, MD, USA., Iqbal N; AstraZeneca, Gaithersburg, MD, USA., Celiñski A; CenterMed-Centrum Badań Klinicznych, Kraków, Poland.
Source: Diabetes therapy : research, treatment and education of diabetes and related disorders [Diabetes Ther] 2018 Aug; Vol. 9 (4), pp. 1703-1711. Date of Electronic Publication: 2018 May 25.
Publication Type: Journal Article
Journal Info: Publisher: Springer Healthcare Country of Publication: United States NLM ID: 101539025 Publication Model: Print-Electronic Cited Medium: Print ISSN: 1869-6953 (Print) Linking ISSN: 18696961 NLM ISO Abbreviation: Diabetes Ther Subsets: PubMed not MEDLINE
Database: MEDLINE Ultimate
Full text is not displayed to guests.
FullText Links:
  – Type: pdflink
Text:
  Availability: 1
Header DbId: mdl
DbLabel: MEDLINE Ultimate
An: 29802530
AccessLevel: 2
PubType: Academic Journal
PubTypeId: academicJournal
PreciseRelevancyScore: 0
IllustrationInfo
Items – Name: Title
  Label: Title
  Group: Ti
  Data: Characterization of the Open-Label Lead-In Period of Two Randomized Controlled Phase 3 Trials Evaluating Dapagliflozin, Saxagliptin, and Metformin in Type 2 Diabetes.
– Name: Author
  Label: Authors
  Group: Au
  Data: <searchLink fieldCode="AU" term="%22Mathieu+C%22">Mathieu C</searchLink>; Katholieke Universiteit Leuven, Leuven, Belgium. chantal.mathieu@uzleuven.be.<br /><searchLink fieldCode="AU" term="%22Catrinoiu+D%22">Catrinoiu D</searchLink>; Spitalul Clinic Judetean de Urgenta Constanta, Constanţa, Romania.<br /><searchLink fieldCode="AU" term="%22Ranetti+AE%22">Ranetti AE</searchLink>; Carol Davila University of Medicine and Pharmacy, Bucharest, Romania.<br /><searchLink fieldCode="AU" term="%22Johnsson+E%22">Johnsson E</searchLink>; AstraZeneca Gothenburg, Mölndal, Sweden.<br /><searchLink fieldCode="AU" term="%22Hansen+L%22">Hansen L</searchLink>; Bristol-Myers Squibb, Princeton, NJ, USA.<br /><searchLink fieldCode="AU" term="%22Chen+H%22">Chen H</searchLink>; AstraZeneca, Gaithersburg, MD, USA.<br /><searchLink fieldCode="AU" term="%22Garcia-Sanchez+R%22">Garcia-Sanchez R</searchLink>; AstraZeneca, Gaithersburg, MD, USA.<br /><searchLink fieldCode="AU" term="%22Iqbal+N%22">Iqbal N</searchLink>; AstraZeneca, Gaithersburg, MD, USA.<br /><searchLink fieldCode="AU" term="%22Celiñski+A%22">Celiñski A</searchLink>; CenterMed-Centrum Badań Klinicznych, Kraków, Poland.
– Name: TitleSource
  Label: Source
  Group: Src
  Data: <searchLink fieldCode="JN" term="%22101539025%22">Diabetes therapy : research, treatment and education of diabetes and related disorders</searchLink> [Diabetes Ther] 2018 Aug; Vol. 9 (4), pp. 1703-1711. <i>Date of Electronic Publication: </i>2018 May 25.
– Name: TypePub
  Label: Publication Type
  Group: TypPub
  Data: Journal Article
– Name: TitleSource
  Label: Journal Info
  Group: Src
  Data: <i>Publisher: </i><searchLink fieldCode="PB" term="%22Springer+Healthcare%22">Springer Healthcare </searchLink><i>Country of Publication: </i>United States <i>NLM ID: </i>101539025 <i>Publication Model: </i>Print-Electronic <i>Cited Medium: </i>Print <i>ISSN: </i>1869-6953 (Print) <i>Linking ISSN: </i><searchLink fieldCode="IS" term="%2218696961%22">18696961 </searchLink><i>NLM ISO Abbreviation: </i>Diabetes Ther <i>Subsets: </i>PubMed not MEDLINE
PLink https://search.ebscohost.com/login.aspx?direct=true&site=eds-live&db=mdl&AN=29802530
RecordInfo BibRecord:
  BibEntity:
    Identifiers:
      – Type: doi
        Value: 10.1007/s13300-018-0445-x
    Languages:
      – Code: eng
        Text: English
    PhysicalDescription:
      Pagination:
        StartPage: 1703
    Titles:
      – TitleFull: Characterization of the Open-Label Lead-In Period of Two Randomized Controlled Phase 3 Trials Evaluating Dapagliflozin, Saxagliptin, and Metformin in Type 2 Diabetes.
        Type: main
  BibRelationships:
    HasContributorRelationships:
      – PersonEntity:
          Name:
            NameFull: Mathieu C
      – PersonEntity:
          Name:
            NameFull: Catrinoiu D
      – PersonEntity:
          Name:
            NameFull: Ranetti AE
      – PersonEntity:
          Name:
            NameFull: Johnsson E
      – PersonEntity:
          Name:
            NameFull: Hansen L
      – PersonEntity:
          Name:
            NameFull: Chen H
      – PersonEntity:
          Name:
            NameFull: Garcia-Sanchez R
      – PersonEntity:
          Name:
            NameFull: Iqbal N
      – PersonEntity:
          Name:
            NameFull: Celiñski A
    IsPartOfRelationships:
      – BibEntity:
          Dates:
            – D: 01
              M: 08
              Text: 2018 Aug
              Type: published
              Y: 2018
          Identifiers:
            – Type: issn-print
              Value: 1869-6953
          Numbering:
            – Type: volume
              Value: 9
            – Type: issue
              Value: 4
          Titles:
            – TitleFull: Diabetes therapy : research, treatment and education of diabetes and related disorders
              Type: main
ResultId 1